Cancers · 2023 · 23 citations · 24 references
MedicineImmunologyOncologyApoptosisCancer ImmunologyTumor MicroenvironmentApoptosis In CancerCancer BiomarkersCancer ImmunotherapyCytotoxic T Lymphocyte ResponsesImmuno-oncology BiomarkersImmunotherapy For Breast CancerCd8 Positive T CellsCd8+ Tumor-infiltrating LymphocytesGranzyme-mediated ApoptosisPreoperative ChemotherapyPrognostic Biomarker DiscoveryRecurrence-free SurvivalTreatment Response BiomarkersTriple-negative Breast Cancer Therapy
Tumor-infiltrating lymphocytes in the tumor microenvironment are important in the treatment of triple-negative breast cancer (TNBC). Cytotoxic T cells produce cytokines and cytotoxic factors, such as perforin and granzyme, which induce apoptosis by damaging target cells. To identify biomarkers of these cells, we investigated granzyme B (GZMB) in the tumor microenvironment as a biomarker of treatment response and prognosis in 230 patients with primary TNBC who underwent surgery without preoperative chemotherapy between January 2004 and December 2014. Programmed cell death ligand 1 (PD-L1) positivity was defined as a composite positive score ≥10 based on the PD-L1 immunostaining of tumor cells and immune cells. GZMB-high was defined as positivity in ≥1% of tumor-infiltrating lymphocytes (TILs). Among the 230 TNBC patients, 117 (50.9%) had CD8-positive infiltrating tumors. In the PD-L1-positive group, a Kaplan–Meier analysis showed that GZMB-high TNBC patients had better recurrence-free survival (RFS) and overall survival (OS) than GZMB-low patients and that OS was significantly longer (RFS: p = 0.0220, OS: p = 0.0254). A multivariate analysis also showed significantly better OS in PD-L1- and GZMB-high patients (hazard ratio: 0.25 (95% IC: 0.07–0.88), p = 0.03). Our findings indicate that GZMB is a useful prognostic biomarker in PD-L1-positive TNBC patients.
24
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder et al. · Science · 2015 · 7.9K citations
Medicine, Immunology, Oncology +17
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst, Jean‐Charles Soria, Marcin Kowanetz et al. · Nature · 2014 · 5.3K citations
Medicine, Immunology, Oncology +16
Antonio C. Wolff, M. Elizabeth H. Hammond, Jared N. Schwartz et al. · Journal of Clinical Oncology · 2006 · 4.5K citations · Full text
Antonio C. Wolff, M. Elizabeth Hammond, David G. Hicks et al. · Journal of Clinical Oncology · 2013 · 4.1K citations · Full text